Kolon TissueGene, Inc. announced that the FDA has allowed the Company to proceed with initiation of a Phase II clinical trial in osteoarthritis (OA) of the hip. Kolon TissueGene has begun activities to initiate the Phase II trial. The Phase II, multicenter, randomized, double-blind, placebo-controlled trial will enroll about 255 patients at over 25 clinical sites across the United States. During the trial, the company will assess the effectiveness, evaluate the safety, and find the optimal dose for TG-C in hip OA. The trial will assess pain improvement in hip OA and measure TG-C effects on structural features of the hip joint via X-ray, as well as assess quality-of-life improvements.